Renhuang Pharmaceuticals, Inc., a leading provider of natural health care products in China, announced guidance for the three months ending October 31, 2006, which is the fourth quarter of the Company's Chinese operating subsidiary fiscal year.

The Company expects to reach a new record for quarterly earnings during the August to October quarter. The Company estimates that net income will be US$2.8 to US$3.0 million, compared to US$2.6 million dollars in the third quarter of 2006. Revenue is expected to be between US$8.5 and US$9 million.

Renhuang Pharmaceuticals is a leading bio-pharmaceutical company located in Harbin in the Heilongjiang Province in Northeast China. Renhuang is primarily engaged in the research, production, and sales of bio-pharmaceutical products in Mainland China. The Company's main products are Siberian ginseng, shark liver oil and several other traditional medical products. It is estimated that 70% of China's natural supply of Siberian Ginseng is currently controlled by the Company.

The company also anticipates approval within six to nine months by State Food and Drug Administration ("SFDA") for up to five of its new Monoclonal Antibody Reagent Box series products. These products are 60% more reliable than those from its competitors and also adhere to "Good Manufacturing Practices", or "GMP".

Moreover, the company is in the process of building its own immune system research and development function. Overall, the company is able to achieve significant cost savings compared to most of its competitors, who purchase their raw materials from third parties.

Source:佚名